X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ensifentrine
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RPL554
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: IQVIA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
Details:
Ensifentrine delivered by pMDI met all of the primary and secondary lung function endpoints in the 7 day, Phase 2 clinical trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Acalabrutinib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Calquence
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
The addition of Calquence to best supportive care (BSC) did not increase the proportion of patients who remained alive and free of respiratory failure. No new safety signal for Calquence was observed in the trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: SNG001
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Aerogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 23, 2020
Details:
Synairgen’s SNG001 among the many potential treatments and vaccines to be delivered via Aerogen’s aerosol drug delivery system .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: SNG001
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
SNG001 was well tolerated during the treatment period in a study population that was elderly (mean age 66 years) and suffering from reduced respiratory function, as
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
